HK1064673A1 - Fused-polycyclic compounds - Google Patents

Fused-polycyclic compounds

Info

Publication number
HK1064673A1
HK1064673A1 HK04107642.3A HK04107642A HK1064673A1 HK 1064673 A1 HK1064673 A1 HK 1064673A1 HK 04107642 A HK04107642 A HK 04107642A HK 1064673 A1 HK1064673 A1 HK 1064673A1
Authority
HK
Hong Kong
Prior art keywords
fused
polycyclic compounds
phosphodiesterase
chem
inhibitor
Prior art date
Application number
HK04107642.3A
Other languages
English (en)
Inventor
Tatsuzo Ukita
Yoshihiro Terakawa
Kazuteru Wada
Aya Nakata
Atsuko Sakai
Koji Ogawa
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of HK1064673A1 publication Critical patent/HK1064673A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK04107642.3A 2001-08-09 2004-10-05 Fused-polycyclic compounds HK1064673A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001241517 2001-08-09
JP2001241502 2001-08-09
JP2001241521 2001-08-09
PCT/JP2002/007783 WO2003016279A1 (fr) 2001-08-09 2002-07-31 Composes polycycliques fusionnes

Publications (1)

Publication Number Publication Date
HK1064673A1 true HK1064673A1 (en) 2005-04-08

Family

ID=27347300

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107642.3A HK1064673A1 (en) 2001-08-09 2004-10-05 Fused-polycyclic compounds

Country Status (15)

Country Link
US (4) US7153859B2 (xx)
EP (1) EP1424326B1 (xx)
KR (1) KR100622879B1 (xx)
CN (1) CN1266134C (xx)
AR (1) AR038781A1 (xx)
AT (1) ATE396972T1 (xx)
AU (1) AU2002325493B2 (xx)
CA (1) CA2455298C (xx)
DE (1) DE60226878D1 (xx)
ES (1) ES2305278T3 (xx)
HK (1) HK1064673A1 (xx)
MX (1) MXPA04001171A (xx)
MY (1) MY129094A (xx)
TW (1) TWI221838B (xx)
WO (1) WO2003016279A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005131943A (ru) * 2003-03-17 2006-03-20 Киова Хакко Когио Ко., Лтд. (Jp) Лечебные и/или профилактические средства для хронических болезней кожи
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
US20060239927A1 (en) * 2003-03-31 2006-10-26 Kyowa Hakko Kogyo Co., Drug for airway administration
WO2004087147A1 (ja) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co., Ltd. 肺疾患の治療および／または予防剤
JPWO2005056009A1 (ja) * 2003-12-12 2007-07-05 協和醗酵工業株式会社 肺疾患治療剤
TWI339578B (en) * 2004-10-29 2011-04-01 Mitsubishi Tanabe Pharma Corp Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
JP6505023B2 (ja) 2013-02-19 2019-04-24 ファイザー・インク Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
MX2017001565A (es) 2014-08-06 2017-04-27 Pfizer Compuestos de imidazopiridazina.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678501A (en) * 1981-07-30 1987-07-07 Union Carbide Corporation Certain pyrazinyl 1,3 cycloalkanedione derivatives having herbicidal activity
JP3042156B2 (ja) * 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
IL118469A (en) 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
DE19617864A1 (de) 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
GB9614718D0 (en) 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
HU225158B1 (en) 1996-10-02 2006-07-28 Janssen Pharmaceutica Nv Pde iv inhibiting 2-(cyanoimino)imidazole derivatives, their use, process for producing them and pharmaceutical compositions containing them
JP2000063275A (ja) 1998-06-12 2000-02-29 Tanabe Seiyaku Co Ltd 医薬組成物
AU5305299A (en) * 1998-08-26 2000-03-21 Tanabe Seiyaku Co., Ltd. Naphthyridine derivatives and process for the preparation thereof
CA2413510C (en) 2000-06-26 2007-12-11 Lilly Icos Llc Condensed pyrazindione derivatives
AU2001296699A1 (en) 2000-11-08 2002-05-21 Lilly Icos Llc Condensed pyrazindione derivatives as pde inhibitors
WO2002094321A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos

Also Published As

Publication number Publication date
EP1424326A4 (en) 2005-08-17
AU2002325493B2 (en) 2005-06-09
MXPA04001171A (es) 2004-05-20
CN1266134C (zh) 2006-07-26
KR20040023742A (ko) 2004-03-18
EP1424326A1 (en) 2004-06-02
US20070010521A1 (en) 2007-01-11
US7550475B2 (en) 2009-06-23
US7550464B2 (en) 2009-06-23
US20040204418A1 (en) 2004-10-14
WO2003016279A1 (fr) 2003-02-27
EP1424326B1 (en) 2008-05-28
DE60226878D1 (de) 2008-07-10
TWI221838B (en) 2004-10-11
US20070004739A1 (en) 2007-01-04
MY129094A (en) 2007-03-30
KR100622879B1 (ko) 2006-09-14
ES2305278T3 (es) 2008-11-01
US7153859B2 (en) 2006-12-26
US20070004740A1 (en) 2007-01-04
CN1538959A (zh) 2004-10-20
AR038781A1 (es) 2005-01-26
US7550476B2 (en) 2009-06-23
CA2455298A1 (en) 2003-02-27
CA2455298C (en) 2009-10-13
ATE396972T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
ZA200309887B (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
HK1056876A1 (en) Ethylenedianme derivatives
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
EP1221439A4 (en) TETRAHYDROQUINOLINE DERIVATIVES
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
WO2003082205A3 (en) Compounds and methods
PT1345896E (pt) Formas cristalinas de atorvastatina
WO2005061458A3 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2002074726A3 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
HK1076816A1 (xx)
WO2003049690A3 (en) Hiv integrase inhibitors
EP1101755A4 (en) ANTHRANILIC ACID DERIVATIVES
WO2003053971A8 (en) Pyridoquinoxaline antivirals
PL340658A1 (en) Derivatives of biphenylamidine
HK1064673A1 (en) Fused-polycyclic compounds
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
FI952420A (fi) Glukopyranosidibentsotiofeenit
EP1253139A3 (en) Multioligoanilinated fullerenes
GR3034746T3 (en) Akyl Substituted heterocyclic compounds.
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
MXPA03007309A (es) Derivados de amina sustituidos por tiofeno como inhibidores glyt-1.
EP1557407A4 (en) NEW ALPHA-CETOAMIDE DERIVATIVE AND USE THEREOF
IL155183A0 (en) Pharmaceutical compositions containing oxapenem-3-carboxylic acids
IL166313A0 (en) Indoline derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150731